Effect of chenodeoxycholic acid and sodium hydrogen sulfide in dinitro benzene sulfonic acid (DNBS) - Induced ulcerative colitis in rats

Pharmacological Reports

Volumn 67, Issue 3, 2015, Pages 616-623

  Goyal, Nidhi ^a   Rana, Ajay ^a   Bijjem, Krishna Reddy V ^a   Kumar, Puneet ^a  

^a ISF COLLEGE OF PHARMACY   (India)

Author keywords

2,4 Dinitrobenzene sulfonic acid; Farnesoid X receptor; hydrogen sulfide; oxidative stress; Ulcerative colitis

Indexed keywords

2,4 DINITROBENZENE SULFONIC ACID; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CATALASE; CHENODEOXYCHOLIC ACID; CYSTATHIONINE GAMMA LYASE; GLUTATHIONE; HYDROGEN SULFIDE; MALONALDEHYDE; MYELOPEROXIDASE; NITRITE; NITROBENZENE DERIVATIVE; PROPARGYLGLYCINE; SALAZOSULFAPYRIDINE; SODIUM HYDROGEN SULFIDE; UNCLASSIFIED DRUG; 1 FLUORO 2,4 DINITROBENZENE; 2,4-DINITROFLUOROBENZENE SULFONIC ACID; SODIUM BISULFIDE; SULFIDE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOODY DIARRHEA; CONTROLLED STUDY; DISEASE ACTIVITY SCORE; DRUG EFFECT; DRUG POTENTIATION; HEART HEMODYNAMICS; NONHUMAN; OXIDATIVE STRESS; RAT; ULCERATIVE COLITIS; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; ANIMAL; CHEMICALLY INDUCED; COLITIS, ULCERATIVE; COMBINATION DRUG THERAPY; FEMALE; MALE; PATHOLOGY; TREATMENT OUTCOME; WISTAR RAT;

ANIMALS; CHENODEOXYCHOLIC ACID; COLITIS, ULCERATIVE; DINITROFLUOROBENZENE; DRUG THERAPY, COMBINATION; FEMALE; MALE; RATS; RATS, WISTAR; SULFIDES; TREATMENT OUTCOME;

EID: 84925235488     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/j.pharep.2014.12.018     Document Type: Article

References (25)

1. K.A. Head, and J.S. Jurenka Inflammatory bowel disease Part 1: Ulcerative colitis - pathophysiology and conventional and alternative treatment options Altern Med Rev 8 3 2003 247
2. P. Rutgeerts, W.J. Sandborn, B.G. Feagan, W. Reinisch, A. Olson, and J. Johanns et al. Infliximab for induction and maintenance therapy for ulcerative colitis New Engl J Med 353 23 2005 2462 2476
3. J. Burisch Crohn's disease and ulcerative colitis. Occurrence, course and prognosis during the first year of disease in a European population-based inception cohort Dan Med J 61 1 2014 B4778
4. J.L. Wallace, T. Le, L. Carter, C.B. Appleyard, and P.L. Beck Hapten-induced chronic colitis in the rat: alternatives to trinitrobenzene sulfonic acid J Pharmacol Toxicol Methods 33 1995 237 239
5. N. Goyal, A. Rana, A. Ahlawat, K.R.V. Bijjem, and P. Kumar Animal models of inflammatory bowel disease: a review Inflammopharmacology 2014 1 15
6. R.M. Gadaleta, S.W. van Mil, B. Oldenburg, P.D. Siersema, L.W. Klomp, and K.J. van Erpecum Bile acids and their nuclear receptor FXR: relevance for hepatobiliary and gastrointestinal disease BBA - Mol Cell Biol Lipids 1801 7 2010 683 692
7. P. Vavassori, A. Mencarelli, B. Renga, E. Distrutti, and S. Fiorucci The bile acid receptor FXR is a modulator of intestinal innate immunity J Immunol 183 2009 6251 6261
8. S. Fiorucci, A. Mencarelli, S. Cipriani, B. Renga, G. Palladino, and L. Santucci et al. Activation of the Farnesoid-X receptor protects against gastrointestinal injury caused by non-steroidal anti-inflammatory drugs in mice Br J Pharmacol 164 8 2011 1929 1938
9. S.V. Joshi, B.A. Vyas, P.D. Shah, D.R. Shah, S.A. Shah, and T.R. Gandhi Protective effect of aqueous extract of Oroxylum indicum Linn (root bark) against DNBS-induced colitis in rats Indian J Pharmacol 43 6 2011 656
10. H. Shifrin, M. Nadler-Milbauer, S. Shoham, and M. Weinstock Rivastigmine alleviates experimentally induced colitis in mice and rats by acting at central and peripheral sites to modulate immune responses PLOS ONE 8 2 2013 e57668
11. E.D. Wills Mechanisms of lipid peroxide formation in animal tissues Biochem J 99 1966 667 676
12. K.V.H. Sastry, R.P. Moudgal, J. Mohan, J.S. Tyagi, and G. Rao Spectrophotometric determination of serum nitrite and nitrate by copper-cadmium alloy Anal Biochem 306 1 2002 79 82
13. G.L. Ellman Tissue sulfhydryl groups Arch Biochem Biophys 82 1 1959 70 77
14. H. Luck Catalase H.U. Bergmeyer, Methods of enzymatic analysis 1971 Academic Press New York 885 893
15. O. Langendorff Untersuchungen am iiberlebenden Saugetierherzen Pflugers Archiv 61 1898 291 332
16. A. Schirbel, and C. Fiocchi Inflammatory bowel disease: established and evolving considerations on its etiopathogenesis and therapy J Dig Dis 11 2010 266 276
17. I. Ordás, L. Eckmann, M. Talamini, D.C. Baumgart, and W.J. Sandborn Ulcerative colitis Lancet 380 2012 1606 1619
18. C.D. Tran, R. Katsikeros, and S.M. Abimosleh Current and Novel Treatments for Ulcerative Colitis M. Shennak, Ulcerative Colitis from Genetics to Complications 2012 InTech 978-953-307-853-3 http://dx.doi.org/10.5772/25592
19. G. Dothel, V. Vasina, G. Barbara, and F.D. Ponti Animal models of chemically induced intestinal inflammation: predictivity and ethical issues Pharmacol Ther 139 1 2013 71 86
20. D.M. McCafferty Peroxynitrite and inflammatory bowel disease Gut 46 2000 436 439
21. J.L. Wallace Release of platelet-activating factor (PAF) and accelerated healing induced by a PAF antagonist in an animal model of chronic colitis Can J Physiol Pharmacol 66 4 1988 422 425
22. S. Cuzzocrea, E. Mazzon, R. Di Paola, N.S. Patel, T. Genovese, and C. Muià Erythropoietin reduces the development of experimental inflammatory bowel disease J Pharmacol Exp Ther 311 3 2004 1272 1280
23. R.J. Xavier, and D.K. Podolsky Unravelling the pathogenesis of inflammatory bowel disease Nature 448 2007 427 434
24. R.M. Gadaleta, K.J. van Erpecum, B. Oldenburg, E.C. Willemsen, W. Renooij, and S. Murzilli Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease Gut 2011 http:// dx.doi.org/10.1136/gut.2010.212159
25. J.L. Wallace Hydrogen sulfide-releasing anti-inflammatory drugs Trends Pharmacol Sci 28 2007 501 505